Detalhe da pesquisa
1.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Diabetologia
; 62(3): 373-386, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30593607
2.
Development and characterisation of a novel glucagon like peptide-1 receptor antibody.
Diabetologia
; 61(3): 711-721, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29119245
3.
Use of CRISPR/Cas9-engineered INS-1 pancreatic ß cells to define the pharmacology of dual GIPR/GLP-1R agonists.
Biochem J
; 473(18): 2881-91, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27422784
4.
TRPC channel activation by extracellular thioredoxin.
Nature
; 451(7174): 69-72, 2008 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-18172497
5.
Stimulating intestinal GIP release reduces food intake and body weight in mice.
Mol Metab
; 84: 101945, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653401
6.
Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.
Front Endocrinol (Lausanne)
; 14: 1217021, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37554763
7.
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
J Biol Chem
; 286(7): 5078-86, 2011 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21127073
8.
Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction.
Circ Res
; 106(9): 1507-15, 2010 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-20360246
9.
Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.
Mol Metab
; 55: 101392, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34781035
10.
Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels.
Mol Pharmacol
; 79(6): 1023-30, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21406603
11.
Short-term stimulation of calcium-permeable transient receptor potential canonical 5-containing channels by oxidized phospholipids.
Arterioscler Thromb Vasc Biol
; 30(7): 1453-9, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20378846
12.
Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.
Sci Rep
; 11(1): 22521, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795324
13.
TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan.
BMC Musculoskelet Disord
; 11: 111, 2010 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525329
14.
Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Mol Metab
; 32: 44-55, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32029229
15.
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
Nat Metab
; 2(5): 413-431, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32478287
16.
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition.
J Clin Invest
; 129(9): 3786-3791, 2019 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31403469
17.
A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility.
Circ Res
; 98(11): 1381-9, 2006 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-16675717
18.
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.
Sci Rep
; 8(1): 17545, 2018 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510163
19.
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.
Curr Opin Pharmacol
; 37: 10-15, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802873
20.
Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.
Nat Commun
; 8(1): 1026, 2017 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29044101